# reload+after+2024-01-23 00:47:33.417847
address1§3020 Carrington Mill Blvd.
address2§Suite 475
city§Morrisville
state§NC
zip§27560
country§United States
phone§212 554 4484
fax§212 554 4531
website§https://www.tgtherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
fullTimeEmployees§245
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Michael S. Weiss Esq.', 'age': 57, 'title': 'Chairman, CEO & President', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 1968750, 'exercisedValue': 0, 'unexercisedValue': 2465000}, {'maxAge': 1, 'name': 'Mr. Sean A. Power CPA', 'age': 41, 'title': 'CFO, Corporate Secretary & Treasurer', 'yearBorn': 1982, 'fiscalYear': 2022, 'totalPay': 652600, 'exercisedValue': 0, 'unexercisedValue': 1398200}, {'maxAge': 1, 'name': 'Jenna  Bosco', 'title': 'Senior Vice President of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Adam  Waldman', 'title': 'Chief Commercialization Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§10
compensationRisk§10
shareHolderRightsRisk§5
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§2.324
priceToSalesTrailing12Months§15.677876
currency§USD
dateShortInterest§1702598400
forwardEps§0.01
exchange§NCM
quoteType§EQUITY
shortName§TG Therapeutics, Inc.
longName§TG Therapeutics, Inc.
firstTradeDateEpochUtc§1272893400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d6673518-e04c-3ac1-8be7-75085ffff3ed
gmtOffSetMilliseconds§-18000000
targetHighPrice§41.0
targetLowPrice§6.0
targetMeanPrice§26.83
targetMedianPrice§24.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§9
quickRatio§4.655
grossMargins§0.96691
ebitdaMargins§-0.098529994
trailingPegRatio§None
